Bristol Myers Squibb Reports 7% Rise in Q3 Revenue to $13.07 Billion and Raises 2026 Sales Outlook

Bristol Myers Squibb (BMY) reported Q3 2026 revenue of $13.07B, up 7% YoY, and raised its 2026 sales outlook to $49.75B-$50.25B. Adjusted EPS was $1.35, beating estimates. Growth Portfolio revenue rose 12%, while adjusted gross margin fell to 68.4%. Shares rose over 2% post-announcement.

Original reporting
Published Oct 29, 2026, 2:50 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 29, 2026, 3:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Bristol Myers Squibb Reports 7% Rise in Q3 Revenue to $13.07 Billion and Raises 2026 Sales Outlook — source image
Decision brief

The 30-second read

$BMYBullishHigh
01

Why it matters

The key tradable change is the raised 2026 revenue forecast and the updated adjusted EPS range, alongside a noted decline in adjusted gross margin tied to product mix and a one-time contract termination charge.

02

Market read

Guidance raise after an earnings beat is a direct catalyst for near-term positioning in BMY and for pharma sentiment around growth portfolio execution.

03

What to watch

The guidance update includes a negative $0.60 per-share impact from acquired in-process R&D charges and licensing income, so investors may scrutinize underlying earnings power versus one-time or accounting effects.

Relevance 9/10Novelty 9/10Timing: post-market reaction day, shares rose more than 2% after the announcement

Background

Bristol Myers Squibb is updating its 2026 full-year outlook after reporting Q3 results that beat analysts on both EPS and revenue.

Company-level read

Ticker impact

$BMYBullishHigh confidence
Context

Bristol Myers Squibb reported Q3 EPS of $1.35 and revenue of $13.07B, then raised 2026 revenue guidance to $49.75B-$50.25B.

Expected impact

Likely upward pressure as the market prices in the higher 2026 revenue midpoint and the updated adjusted EPS range.

Evidence & confidence

The article is a first-report earnings and guidance update with explicit upside to revenue guidance and a Q3 beat on both EPS and revenue.

Market effects

Signals continued demand and execution in large-cap pharma, potentially supporting sentiment toward oncology and legacy brands.

Primarily US large-cap pharma sentiment; limited direct spillover beyond the sector.

Moderate, as guidance updates can influence global pharma peers’ read-through on demand and margin trajectory.

Counterpoint

The adjusted gross margin fell to 68.4% from 72.9%, which could cap upside if investors focus on profitability deterioration despite revenue growth.

Key entities

  • Bristol Myers Squibb

    Reported Q3 2026 results and raised 2026 revenue guidance; updated adjusted EPS guidance.

Related articles

$BMYMed

Deucravacitinib Linked to Arthritis Improvements in SLE

Deucravacitinib, a drug developed by Bristol Myers Squibb, showed improvements in arthritis symptoms for 60% of SLE patients with active joints in a 48-week study. Patients taking 3 mg twice daily had higher odds of joint count reductions compared to placebo. The study was published in Lupus Science & Medicine.

$LLYMedAI 8/10

Rx Rundown: Ollin Biosciences, AstraZeneca, Isomorphic Labs and more

Eli Lilly, AbbVie, Johnson & Johnson, and others announced major deals and acquisitions in the biopharma sector, totaling billions. AstraZeneca, Roche, and Novo Nordisk received FDA approvals for new treatments. Isomorphic Labs raised $5 billion in private financing. AstraZeneca cut 600 jobs, while Cellectis plans to cut 70% of its workforce.

$OMCLow

Omnicom Media Retains Bristol Myers Squibb Account

Omnicom Media retained Bristol Myers Squibb's US media account, adding healthcare professional media responsibilities. The account had been handled by IPG Mediabrands, acquired by Omnicom. Bristol Myers Squibb's 2023 media budget was $430 million. This follows Omnicom's win of Novo Nordisk's US media buying business from WPP.

$EVOMedAI 8/10

Evotec and Bristol Myers Squibb Advance Strategic Protein Degradation Partnership with Second IND Acceptance

Evotec (EVO) and Bristol Myers Squibb received FDA clearance for a second Investigational New Drug (IND) in their protein degradation partnership. The first candidate entered Phase 1 trials in March 2026, and the second is expected to start in 2027. The collaboration leverages Evotec's drug discovery capabilities and Bristol Myers Squibb's CELMoD agent library to develop molecular glue degraders for oncology and other therapeutic areas.